Patents by Inventor Hiroshi Nara
Hiroshi Nara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11986480Abstract: Provided is a novel compound or salt thereof that induces degradation by autophagy of an intracellular molecule. In this compound, a ligand having activity to bind to an intracellular molecule and a structure having activity to induce autophagy of an intracellular molecule are linked via a linker without loss of the activity of the ligand and the structure.Type: GrantFiled: February 2, 2018Date of Patent: May 21, 2024Assignee: TOHOKU UNIVERSITYInventors: Hirokazu Arimoto, Kaori Itto, Daiki Takahashi, Nobuo Cho, Hiroshi Nara, Kenichiro Shimokawa, Taiichi Ohra, Shigekazu Sasaki, Naoki Ishii
-
Patent number: 11572921Abstract: A sintered bearing is made of a sintered compact containing nickel silver (Cu—Ni—Zn) as a base. In the sintered bearing, P is not added in the sintered compact. Alternatively, a content of P in the sintered compact is less than 0.05 mass % in terms of mass ratio to a total mass. Consequently, crystal grains constituting the sintered compact can be micronized. In particular, in the sintered bearing, an average crystal particle diameter of the crystal grains constituting the sintered compact is 20 ?m or less. Consequently, the mechanical strength and the vibration resisting properties can be improved, and the rotation shaft can be prevented from being damaged.Type: GrantFiled: January 25, 2019Date of Patent: February 7, 2023Assignee: PORITE CORPORATIONInventors: Shigeyuki Tanabe, Shinobu Aso, Hiroshi Nara
-
Patent number: 11495331Abstract: An objective of the present invention is to provide a document creation assistance server and document creation assistance method which are capable of efficiently acquiring information necessary to write a specification or other such documents, and of generating a document from the acquired information.Type: GrantFiled: September 10, 2018Date of Patent: November 8, 2022Assignees: TAKEDA PHARMACEUTICAL COMPANY LIMITED, PATCORE, INC.Inventors: Hiroshi Nara, Junya Shirai, Tatsuki Koike, Kenjiro Sato, Takaharu Hirayama, Hiromi Fukuda, Tsutomu Morita, Hiromasa Ishihara, Kazue Suzuki, Hiroki Sakamoto, Fumiaki Kikuchi, Kenta Tamaki, Toru Tanoue, Yuichi Horita, Takeshi Ueda
-
Patent number: 11401264Abstract: The present invention provides a heterocyclic compound having an activity to promote the maturation of a cardiomyocyte. A compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof has an activity to promote the maturation of a cardiomyocyte, and is useful as a cardiomyocyte maturation promoter.Type: GrantFiled: March 28, 2019Date of Patent: August 2, 2022Assignee: Orizuru Therapeutics, Inc.Inventors: Yoshinori Yoshida, Kenji Miki, Akira Kaieda, Shigeru Kondo, Hiroshi Nara, Yoshinori Ikeura
-
Publication number: 20210040989Abstract: A sintered bearing is made of a sintered compact containing nickel silver (Cu—Ni—Zn) as a base. In the sintered bearing, P is not added in the sintered compact. Alternatively, a content of P in the sintered compact is less than 0.05 mass % in terms of mass ratio to a total mass. Consequently, crystal grains constituting the sintered compact can be micronized. In particular, in the sintered bearing, an average crystal particle diameter of the crystal grains constituting the sintered compact is 20 ?m or less. Consequently, the mechanical strength and the vibration resisting properties can be improved, and the rotation shaft can be prevented from being damaged.Type: ApplicationFiled: January 25, 2019Publication date: February 11, 2021Inventors: Shigeyuki TANABE, Shinobu ASO, Hiroshi NARA
-
Publication number: 20210024512Abstract: The present invention provides a heterocyclic compound having an activity to promote the maturation of a cardiomyocyte. A compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof has an activity to promote the maturation of a cardiomyocyte, and is useful as a cardiomyocyte maturation promoter.Type: ApplicationFiled: March 28, 2019Publication date: January 28, 2021Applicants: Kyoto University, Takeda Pharmaceutical Company LimitedInventors: Yoshinori YOSHIDA, Kenji MIKI, Akira KAIEDA, Shigeru KONDO, Hiroshi NARA, Yoshinori IKEURA
-
Publication number: 20200388354Abstract: An objective of the present invention is to provide a document creation assistance server and document creation assistance method which are capable of efficiently acquiring information necessary to write a specification or other such documents, and of generating a document from the acquired information.Type: ApplicationFiled: September 10, 2018Publication date: December 10, 2020Inventors: Hiroshi NARA, Junya SHIRAI, Tatsuki KOIKE, Kenjiro SATO, Takaharu HIRAYAMA, Hiromi FUKUDA, Tsutomu MORITA, Hiromasa ISHIHARA, Kazue SUZUKI, Hiroki SAKAMOTO, Fumiaki KIKUCHI, Kenta TAMAKI, Toru TANOUE, Yuichi HORITA, Takeshi UEDA
-
Publication number: 20200163970Abstract: Provided is a novel compound or salt thereof that induces degradation by autophagy of an intracellular molecule. In this compound, a ligand having activity to bind to an intracellular molecule and a structure having activity to induce autophagy of an intracellular molecule are linked via a linker without loss of the activity of the ligand and the structure.Type: ApplicationFiled: February 2, 2018Publication date: May 28, 2020Inventors: Hirokazu ARIMOTO, Kaori ITTO, Daiki TAKAHASHI, Nobuo CHO, Hiroshi NARA, Kenichiro SHIMOKAWA, Taiichi OHRA, Shigekazu SASAKI, Naoki ISHII
-
Patent number: 10406146Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of inflammatory disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: August 24, 2016Date of Patent: September 10, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Akira Kaieda, Naoki Ishii, Hiroshi Nara, Masato Yoshikawa, Masaki Daini
-
Patent number: 10357484Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: July 15, 2016Date of Patent: July 23, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Akira Kaieda, Masaki Daini, Hiroshi Nara, Masato Yoshikawa, Naoki Ishii, Masashi Toyofuku, Kousuke Hidaka
-
Patent number: 10308643Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: July 15, 2016Date of Patent: June 4, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Akira Kaieda, Masashi Toyofuku, Masaki Daini, Hiroshi Nara, Masato Yoshikawa, Naoki Ishii, Kousuke Hidaka
-
Publication number: 20190008836Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: July 15, 2016Publication date: January 10, 2019Inventors: Akira KAIEDA, Masaki DAINI, Hiroshi NARA, Masato YOSHIKAWA, Naoki ISHII, Masashi TOYOFUKU, Kousuke HIDAKA
-
Patent number: 10081624Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: August 25, 2015Date of Patent: September 25, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Akira Kaieda, Naoki Ishii, Hiroshi Nara, Masato Yoshikawa, Masaki Daini, Masashi Toyofuku, Kousuke Hidaka
-
Publication number: 20180263967Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of inflammatory disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: August 24, 2016Publication date: September 20, 2018Inventors: Akira KAIEDA, Naoki ISHII, Hiroshi NARA, Masato YOSHIKAWA, Masaki DAINI
-
Publication number: 20180222896Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: August 25, 2015Publication date: August 9, 2018Applicant: Takeda Pharmaceutical Company LimitedInventors: Akira Kaieda, Noaki Ishii, Hiroshi Nara, Masato Yoshikawa, Masaki Daini, Mashashi Toyofuku, Kousuke Hidaka
-
Patent number: 10038882Abstract: A projector and a method of controlling the projector that may give information on suitability of a light source. A projector includes light sources, light modulators (liquid crystal panels) that modulate lights output from the light sources, a projection optical device that projects the lights modulated by the light modulators, a determination unit that determines whether or not a light source unadapted to a mounting position of the projector is attached, and an informing unit (display control unit) that, if a determination that the light source unadapted to the mounting position of the projector is attached is made by the determination unit, gives information in response to a determination result.Type: GrantFiled: February 27, 2015Date of Patent: July 31, 2018Assignee: SEIKO EPSON CORPORATIONInventors: Takanori Fukuyama, Hiroshi Nara, Kazunori Maeta, Kaname Nagatani
-
Publication number: 20180118708Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of autoimmune disease and/or inflammatory disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).Type: ApplicationFiled: May 6, 2016Publication date: May 3, 2018Applicant: Takeda Pharmaceutical Company LimitedInventors: Toshitake KOBAYASHI, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
-
Patent number: 9828357Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.Type: GrantFiled: November 21, 2016Date of Patent: November 28, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Toshitake Kobayashi, Morihisa Saitoh, Yasufumi Wada, Hiroshi Nara, Nobuyuki Negoro, Taisuke Katoh, Masashi Yamasaki, Takahiro Tanaka, Naomi Kitamoto
-
Patent number: 9611244Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).Type: GrantFiled: May 6, 2016Date of Patent: April 4, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Toshitake Kobayashi, Morihisa Saitoh, Yasufumi Wada, Hiroshi Nara, Nobuyuki Negoro
-
Publication number: 20170066737Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.Type: ApplicationFiled: November 21, 2016Publication date: March 9, 2017Applicant: Takeda Pharmaceutical Company LimitedInventors: Toshitake Kobayashi, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Taisuke KATOH, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO